{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T20:33:32Z","timestamp":1774730012483,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-024-08592-x","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T08:33:14Z","timestamp":1732177994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prochlorperazine maleate versus placebo for the prevention of acute mountain sickness: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4949-0587","authenticated-orcid":false,"given":"Elan","family":"Small","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Musi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda E.","family":"Keyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"issue":"19","key":"8592_CR1","doi-asserted-by":"publisher","first-page":"e023225","DOI":"10.1161\/JAHA.121.023225","volume":"10","author":"WK Cornwell 3rd","year":"2021","unstructured":"Cornwell WK 3rd, Baggish AL, Bhatta YKD, et al. Clinical implications for exercise at altitude among individuals with cardiovascular disease: a scientific statement from the American Heart Association. J Am Heart Assoc. 2021;10(19):e023225.","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"8592_CR2","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMcp1214870","volume":"368","author":"P Bartsch","year":"2013","unstructured":"Bartsch P, Swenson ER. Clinical practice: acute high-altitude illnesses. N Engl J Med. 2013;368(24):2294\u2013302.","journal-title":"N Engl J Med"},{"issue":"6756","key":"8592_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/bmj.301.6756.853","volume":"301","author":"M Maggiorini","year":"1990","unstructured":"Maggiorini M, Buhler B, Walter M, Oelz O. Prevalence of acute mountain sickness in the Swiss Alps. BMJ. 1990;301(6756):853\u20135.","journal-title":"BMJ"},{"issue":"S1","key":"8592_CR4","first-page":"4","volume":"58","author":"DW Dodick","year":"2018","unstructured":"Dodick DW. A phase-by-phase review of migraine pathophysiology. Headache: The Journal of Head and Face. Pain. 2018;58(S1):4\u201316.","journal-title":"Pain"},{"issue":"2","key":"8592_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/ham.2013.1151","volume":"15","author":"MH Wilson","year":"2014","unstructured":"Wilson MH, Wright A, Imray CH. Intracranial pressure at altitude. High Alt Med Biol. 2014;15(2):123\u201332.","journal-title":"High Alt Med Biol"},{"issue":"5","key":"8592_CR6","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.mehy.2011.07.045","volume":"77","author":"MW Kim","year":"2011","unstructured":"Kim MW, Kim M. Can migraine prophylaxis prevent acute mountain sickness at high altitude? Med Hypotheses. 2011;77(5):818\u201323.","journal-title":"Med Hypotheses"},{"issue":"3","key":"8592_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/ana.21162","volume":"62","author":"S Jafarian","year":"2007","unstructured":"Jafarian S, Gorouhi F, Salimi S, Lotfi J. Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Ann Neurol. 2007;62(3):273\u20137.","journal-title":"Ann Neurol"},{"issue":"1","key":"8592_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.wem.2019.11.005","volume":"31","author":"HR Irons","year":"2020","unstructured":"Irons HR, Salas RN, Bhai SF, Gregorie WD, Harris NS. Prospective double-blinded randomized field-based clinical trial of metoclopramide and ibuprofen for the treatment of high altitude headache and acute mountain sickness. Wilderness Environ Med. 2020;31(1):38\u201343.","journal-title":"Wilderness Environ Med"},{"issue":"2","key":"8592_CR9","first-page":"137","volume":"1","author":"HS Smith","year":"2012","unstructured":"Smith HS, Cox LR, Smith BR. Dopamine receptor antagonists. Ann Palliative Med. 2012;1(2):137\u201342.","journal-title":"Ann Palliative Med"},{"issue":"6","key":"8592_CR10","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/head.12835","volume":"56","author":"SL Orr","year":"2016","unstructured":"Orr SL, Friedman BW, Christie S, et al. Management of adults with acute migraine in the emergency department: the American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache. 2016;56(6):911\u201340.","journal-title":"Headache"},{"issue":"5","key":"8592_CR11","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/head.13527","volume":"59","author":"I Golikhatir","year":"2019","unstructured":"Golikhatir I, Cheraghmakani H, Bozorgi F, Jahanian F, Sazgar M, Montazer SH. The efficacy and safety of prochlorperazine in patients with acute migraine: a systematic review and meta-analysis. Headache: 2019;59(5):682\u2013700.","journal-title":"Headache:"},{"issue":"2","key":"8592_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/head.12026","volume":"53","author":"A Charles","year":"2013","unstructured":"Charles A. The evolution of a migraine attack - a review of recent evidence. Headache. 2013;53(2):413\u20139.","journal-title":"Headache"},{"issue":"3","key":"8592_CR13","first-page":"637","volume":"53","author":"LG Olson","year":"1982","unstructured":"Olson LG, Hensley MJ, Saunders NA. Augmentation of ventilatory response to asphyxia by prochlorperazine in humans. J Appl Physiol Respir Environ Exerc Physiol. 1982;53(3):637\u201343.","journal-title":"J Appl Physiol Respir Environ Exerc Physiol"},{"issue":"2","key":"8592_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1164\/rccm.201108-1396OC","volume":"185","author":"JP Richalet","year":"2012","unstructured":"Richalet JP, Larmignat P, Poitrine E, Letournel M, Canou\u00ef-Poitrine F. Physiological risk factors for severe high-altitude illness: a prospective cohort study. Am J Respir Crit Care Med. 2012;185(2):192\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"8592_CR15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1046\/j.1526-4610.2002.02210.x","volume":"42","author":"S Sharma","year":"2002","unstructured":"Sharma S, Prasad A, Nehru R, et al. Efficacy and tolerability of prochlorperazine buccal tablets in treatment of acute migraine. Headache. 2002;42(9):896\u2013902.","journal-title":"Headache"},{"issue":"5","key":"8592_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1053\/ajem.2000.9283","volume":"18","author":"JC Olsen","year":"2000","unstructured":"Olsen JC, Keng JA, Clark JA. Frequency of adverse reactions to prochlorperazine in the ED. Am J Emerg Med. 2000;18(5):609\u201311 Accessed date: 2000\/09\/01.","journal-title":"Am J Emerg Med"},{"issue":"1","key":"8592_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/ham.2017.0160","volume":"19","author":"M Brodmann Maeder","year":"2018","unstructured":"Brodmann Maeder M, Brugger H, Pun M, et al. The STAR data reporting guidelines for clinical high altitude research. High Alt Med Biol. 2018;19(1):7\u201314 Epub 2018 Feb 9 PMID: 29596018.","journal-title":"High Alt Med Biol"},{"key":"8592_CR18","doi-asserted-by":"crossref","unstructured":"Nieto Estrada VH, Molano Franco D, Medina RD, Gonzalez Garay AG, Mart\u00ed\u2010Carvajal AJ, Arevalo\u2010Rodriguez I. Interventions for preventing high altitude illness: Part 1. Commonly\u2010used classes of drugs. Cochrane Database Syst Rev. 2017;(6):Cd009761.","DOI":"10.1002\/14651858.CD009761.pub2"},{"issue":"1_suppl","key":"8592_CR19","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1016\/j.wem.2023.05.013","volume":"35","author":"AM Luks","year":"2024","unstructured":"Luks AM, Beidleman BA, Freer L, et al. Wilderness Medical Society clinical practice guidelines for the prevention, diagnosis, and treatment of acute altitude illness: 2024 update. Wilderness Environ Med. 2024;35(1_suppl):2S.","journal-title":"Wilderness Environ Med"},{"issue":"1","key":"8592_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1580\/08-WEME-BR-247.1","volume":"20","author":"G Leadbetter","year":"2009","unstructured":"Leadbetter G, Keyes LE, Maakestad KM, Olson S, van Tissot Patot MC, Hackett PH. Ginkgo biloba does--and does not--prevent acute mountain sickness. Wilderness Environ Med. 2009;20(1):66\u201371 Spring.","journal-title":"Wilderness Environ Med"},{"issue":"4","key":"8592_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1089\/ham.2008.1029","volume":"9","author":"MCT van Patot","year":"2008","unstructured":"van Patot MCT, Leadbetter G, Keyes LE, Maakestad KM, Olson S, Hackett PH. Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Altitude Med Biol. 2008;9(4):289\u201393 2008\/12\/01.","journal-title":"High Altitude Med Biol"},{"issue":"4","key":"8592_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4103\/atm.atm_651_20","volume":"16","author":"D Gao","year":"2021","unstructured":"Gao D, Wang Y, Zhang R, Zhang Y. Efficacy of acetazolamide for the prophylaxis of acute mountain sickness: a systematic review, meta-analysis, and trial sequential analysis of randomized clinical trials. Ann Thorac Med. 2021;16(4):337\u201346.","journal-title":"Ann Thorac Med"},{"issue":"1","key":"8592_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1089\/ham.2017.0164","volume":"19","author":"RC Roach","year":"2018","unstructured":"Roach RC, Hackett PH, Oelz O, et al. The 2018 Lake Louise acute mountain sickness score. High Alt Med Biol. 2018;19(1):4\u20136.","journal-title":"High Alt Med Biol"},{"issue":"7996","key":"8592_CR24","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(76)91677-9","volume":"2","author":"PH Hackett","year":"1976","unstructured":"Hackett PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. 1976;2(7996):1149\u201355.","journal-title":"Lancet"},{"issue":"3","key":"8592_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1089\/ham.2019.0007","volume":"20","author":"GS Lipman","year":"2019","unstructured":"Lipman GS, Jurkiewicz C, Winstead-Derlega C, et al. Day of ascent dosing of acetazolamide for prevention of acute mountain sickness. High Alt Med Biol. 2019;20(3):271\u20138.","journal-title":"High Alt Med Biol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08592-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T09:06:08Z","timestamp":1732179968000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08592-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8592"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08592-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Colorado Multiple Institutional Review Board (COMIRB) # 23\u20130958. We will obtain written informed consent to participate from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"The consent form will be provided if requested.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"There are no financial or other competing interests for any study team members.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"785"}}